Equities analysts expect Sientra Inc (NASDAQ:SIEN) to post earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Sientra’s earnings, with estimates ranging from ($0.50) to ($0.41). Sientra posted earnings of ($0.73) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.4%. The firm is scheduled to announce its next earnings report on Thursday, August 13th.
According to Zacks, analysts expect that Sientra will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.57). For the next year, analysts anticipate that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.43) to ($1.15). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Monday, May 11th. The medical instruments supplier reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08). The firm had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $18.70 million. Sientra had a negative return on equity of 101.94% and a negative net margin of 134.87%.
A number of research firms recently issued reports on SIEN. Maxim Group boosted their target price on shares of Sientra from $5.00 to $8.00 in a research report on Thursday, June 11th. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating and set a $5.25 price objective for the company in a research report on Tuesday, July 14th. Canaccord Genuity reduced their price target on shares of Sientra from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, SVB Leerink dropped their price objective on shares of Sientra from $6.50 to $5.30 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $6.26.
Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG raised its holdings in shares of Sientra by 1.3% in the 1st quarter. UBS Group AG now owns 2,428,229 shares of the medical instruments supplier’s stock valued at $4,832,000 after purchasing an additional 32,017 shares in the last quarter. Schroder Investment Management Group lifted its stake in Sientra by 1.7% during the first quarter. Schroder Investment Management Group now owns 1,902,776 shares of the medical instruments supplier’s stock valued at $3,863,000 after buying an additional 31,763 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Sientra by 966.9% during the first quarter. JPMorgan Chase & Co. now owns 1,154,898 shares of the medical instruments supplier’s stock valued at $2,297,000 after buying an additional 1,046,648 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Sientra by 2.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,066,378 shares of the medical instruments supplier’s stock worth $9,533,000 after purchasing an additional 22,925 shares in the last quarter. Finally, Granahan Investment Management Inc. MA lifted its position in shares of Sientra by 6.6% in the first quarter. Granahan Investment Management Inc. MA now owns 809,972 shares of the medical instruments supplier’s stock worth $1,612,000 after purchasing an additional 50,247 shares in the last quarter. Institutional investors and hedge funds own 74.41% of the company’s stock.
Shares of SIEN opened at $3.86 on Monday. The company’s fifty day moving average price is $4.08 and its 200-day moving average price is $4.15. Sientra has a 1-year low of $1.00 and a 1-year high of $9.71. The company has a debt-to-equity ratio of 1.02, a current ratio of 2.24 and a quick ratio of 1.72.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.